Background: Patients with systemic lupus erythematosus (SLE) have a better survival than decades ago. Nevertheless, they still experience low health-related quality of life (HRQoL). The Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQoL) is one of the most widely used specific tools for measuring HRQoL in SLE. 

Objectives: The aim of our study is to assess the impact of the SLE in the HRQoL using the SLEQoL tool.

Methods: This is a cross-sectional study during a period of the year 2020, including patients followed in the departments of Internal Medicine and Rheumatology in Mahdia, Tunisia. All patients were diagnosed with SLE based in ACR 1997/SLICC2012. The SLEQoL is composed of 40 items scored from 1 to 7, it includes six HRQoL domains: physical functioning (Items 1 to 6), activities (Items 7 to 15), symptoms (Items 16 to 23), treatment (Items 24 to 27), mood (Items 28 to 31) and self-image (Items 32 to 40) with higher values corresponding to worse HRQoL.

Results: Forty-six SLE patients were included. The mean age was 47.19±16.45 years. The mean disease duration was 2.3±2.9 years. The mean SLEDAI score was 5.78±4.94. The main target organs involved were cutaneous, musculoskeletal, neurological, pulmonary, cardiovascular and renal in 85%, 82.5%, 32.5%, 17.5%, 15% and 7.5% of cases respectively. The biologic analysis showed the positivity of anti-nuclear antibodies in 97.5% of cases, low serum complement C3 and C4 in 20% and 32.5% of cases respectively. A biological inflammatory syndrome was found in 37.5% of cases and Anemia in 42.5%. 85% of SLE patients were treated by anti-malarial, 62.5% were treated by Glucocorticoids and 5% by Methotrexate.

The mean SLEQoL global score was 77.92±34.02 [40-153]. The means of different domains (physical functioning, activities, symptoms, treatment, mood and self-image) were respectively 12.1±6.49 [6-30]; 19.6±10.9 [9-49]; 16.4±1.8 [8-34]; 5.8±3.9 [0-14]; 9.6±5.4 [4-20]; 14.9±7.5 [9-98]. The most severely impaired domains were activities and symptoms. The less affected domains were treatment and mood. The SLEQoL global score was correlated with increased age (p=0.03), longer disease duration (p=0.05), SLEDAI score (p=0.02), visual manifestations (p=0.05), and pulmonary manifestations (p=0.05). By analyzing biological tests of our patients, we found a correlation between the SLEQoL global score and Erythrocyte sedimentation rate [ESR] (p=0.05). Anemia (p=0.04), low serum complement C3 (p=0.02) and C4 (p=0.003). SLEQoL global score and its six domains were not correlated with gender, educational level nor marital status.

Conclusion: Our study showed that HRQoL is impaired in patients with SLE. The most important predictors of low HRQoL were older age, longer disease duration, some clinical manifestations, biological activity disease indicators (ESR, anemia and low complement level) and the SLEDAI score.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3651

AB0338
PREGNANCY OUTCOMES IN ADOLESCENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

P. Alba1, Y. Tissera1, N. Cicciaro1, V. Savio1, R. Serrano Morales2, M. I. Guajía1, J. A. Albiero1, V. Juarez2, C. A. Gobbi1, M. Yorio1, M. E. Crespo Espindola1, 1Universidad Nacional de Cordoba, Cateda de Semiología, Servicio de Reumatologia Hospital Cordoba, Cordoba, Argentina; 2Hospital Señor del Milagro, Servicio de Reumatologia, Salta, Argentina; 3Centro de Enfermedades autoinmunes y Reumaticas, Maternidad Oroño, Rosario, Argentina; 4Hospital Señor del Milagro, Servicio de Reumatologia, Salta, Argentina; 5Universidad Nacional de Cordoba, Cateda de Medicina I. Servicio de Reumatologia Hospital Cordoba, Cordoba, Argentina

Background: Systemic lupus erythematosus (SLE) is a autoimmune disease that affects adolescents and young women of childbearing age. In spite of the improvement in fetal and maternal SLE pregnancy outcome in the last decades, they have increased risk of adverse outcomes including disease flare, abortions, preeclampsia (PE) and premature birth (PB). However, pregnancy outcomes among adolescents have not been well explored.

Objectives: To evaluate maternal and fetal outcomes in pregnant adolescents with SLE.

Methods: We retrospectively studied all pregnant SLE adolescent patients, who attended to 3 Maternity Hospitals in Argentina in the last 5 years. Demographic, clinical, and laboratory data were collected. The presence of Antiphospholipid Syndrome (APS) and Antiphospholipid antibodies (AA), and maternal and fetal outcome were evaluated. Adolescent pregnancy was defined it happened between 10 and 19 years old. Lupus activity was evaluated by SELENA SLEDAI at the conception and each trimester of pregnancy and puerperium.

Results: 32 pregnancies in 21 patients were included. Mean age was 18 years old, 66% was mestizo ethnicity and mean disease duration of 2 years. Renal involvement was found in 19, Mucocutaneous in 21, and hematological in 14 patients. 4 patients had positive Anti-SSA/Ro antibodies, 1 Anti-SSB/La, 2 Lupus anticoagulant, 6 Ig G ACL, 3 Ig M ACL, and 8 patients fulfilled APS criteria. Activity disease was 0 SELENA SLEDAI in 1st trimester, 4 in 2nd, 3rd trimester and puerperium. Maternal and fetal outcomes are shown in Table 1. Cesarean section was performed in 58% (n=18) of the patients, 6 had abortions and 1 fetal death.

Table 1. Maternal outcomes

<table>
<thead>
<tr>
<th>Disease Flares</th>
<th>PE/HELP</th>
<th>Gestational Diabetes</th>
<th>Gestational outcomes</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>13/41(7) renal</td>
<td>6 (19%)</td>
<td>1 (3%)</td>
<td>3 (12%)</td>
<td>0</td>
</tr>
</tbody>
</table>

Conclusion: Maternal and fetal complications were high in adolescent pregnancy with SLE, including disease activity, PE and PB. A tight control of patients should be performed before and after conception. These patients should be managed by a multidisciplinary team, thus allowing an improvement of maternal and fetal outcomes.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3658

AB0339
PREVALENCE AND ASSOCIATED FACTORS OF LOW BONE MINERAL DENSITY IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

M. Ardaoua1, M. Brahemi1, S. Arfa2, H. Hachiti3, B. Ben Rejeb4, M. Hassayoun5, R. Sarraj6, S. Abdeliatti7, A. Ben Salem8, R. Ben Tekaya9, O. Berniche9, Y. Mohamed10, Taher Star Hospital, Rheumatology, Mahdia, Tunisia; Taher Star Hospital, Internal Medicine, Mahdia, Tunisia

Background: Patients with Systemic Lupus Erythematosus (SLE) are at risk of osteoporosis (OP) and fragility fractures (FFx) because of the disease or its treatments. We assessed the prevalence and risk factors for OP in patients with SLE.

Objectives: Our objective is to determine the prevalence of bone mineral density (BMD) loss and fracture risk factors in SLE patients undergoing dual-energy X-ray absorptiometry (DXA).

Methods: This is a cross sectional study conducted during the year 2020 in the Rheumatology and internal medicine departments in Taher Star Hospital of Mahdia, Tunisia. We included patients aged ≥18 years with a diagnosis of SLE according to the 1997 ACR or 2012 SLICC criteria. Patients with renal or hepatic osteodystrophy, or receiving bisphosphonates were excluded from the study. The BMD values were measured by DXA. The T-score, Z-scores and BMD of the lumbar spine (LS) and femoral neck (FN) were determined. OP was defined as a value of the T-score less or equal to -2.5 SD for postmenopausal women and men aged more than 50 years old, and Z-scores less or equal to -2 for premenopausal women and men aged less than 50 years old.

Results: Forty-six SLE patients were included. The mean age was 47.19±16.45 years [18-85], with a mean disease duration of 2.5±3.46 years [15days-15years]. The mean SLEDAI score was 5.3±4.82. As regards menstrual history of female patients: 56.5% were premenopausal, 43.5% were post-menopausal and 6% had premature menopause. 13% of our patients gave history of smoking. The mean BMI was 27.8 ± 6.9kg/m² [3-9.8]. FFx were diagnosed in 4 patients (9%) and the mean age of the first fracture was 45years. GCs were used in 65.2% of cases (30 patients). The mean daily dose of GCs was 10mg/day and the mean cumulative dose was 20g. Calcium and Vitamin D intake was mentioned in 65.2% of cases (30 patients). The association of SLE with other rheumatic diseases was found in 14 of patients. The mean T-score at FN and LS were respectively 0.2±0.117 and -1.5±0.136. The mean Z-score at FN and LS were respectively 0.53±0.14 and -0.6±1.26. It was found that 17 patients (37% of cases) had OP, 12 had osteopenia (26%) and 17 patients (37%) had normal BMD. 37% of patients had OP at LS, 23.9% osteoporosis at LS, 6.5% OP at FN and 21.7% osteopenia at FN.